| Mar 27 | 2020 |
AVEO Oncology and Biodesix to Discontinue CyFi-2 Study of Ficlatuzumab in Relapsed and Refractory AML in Response to Public Health Crisis |
| Mar 16 | 2020 |
AVEO Oncology Reports Full Year 2019 Financial Results and Provides Business Update |
| Feb 19 | 2020 |
AVEO Announces Effectiveness of 1-for-10 Reverse Stock Split |
| Feb 12 | 2020 |
AVEO Oncology Announces Publication of Phase 1b/2 Study of Tivozanib in Advanced, Inoperable Liver Cancer in the British Journal of Cancer |
| Jan 27 | 2020 |
AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer |
| Jan 6 | 2020 |
AVEO Announces Appointment of Erick J. Lucera as Chief Financial Officer |
